Product Information
SAXAGLIPTIN HCL 5 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $1.0387 per EA under NDC 65862082690. Its NADAC has been published 44 times since Dec 3, 2025.
FDA first approved this application on Jul 31, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862082690
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SAXAGLIPTIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205972FDA Approved
7/31/2023
TE Code
AB
On Market Since
7/31/2023
Pharmacological Classes
Price Statistics
The NADAC for SAXAGLIPTIN HCL 5 MG TABLET has been published 44 times since Dec 3, 2025, and over the history we have for it it has declined 64.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0387 per EA |
|---|---|
| All-time high | $2.9076 (Dec 10, 2025) |
| All-time low | $1.0387 (Sep 23, 2026) |
| 52-week high | $2.9076 |
| 52-week low | $1.0387 |
| Median price | $1.1692 |
| Average price | $1.5088 |
| Largest weekly change | -25.9% (Feb 18, 2026) |
| Weeks tracked | 44 |
| Tracking since | Dec 3, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Saxagliptin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAXAGLIPTIN HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SAXAGLIPTIN HCL 5 MG TABLET, manufactured by Aurobindo Pharma Limited, is $1.0387 per EA (NDC 65862082690), effective Sep 30, 2026.
How has the price of SAXAGLIPTIN HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for SAXAGLIPTIN HCL 5 MG TABLET has declined 64.3%. It has been tracked across 44 weekly CMS publications since Dec 3, 2025.
What are the highest and lowest recorded NADAC prices for SAXAGLIPTIN HCL 5 MG TABLET?
Since Dec 3, 2025, the NADAC for SAXAGLIPTIN HCL 5 MG TABLET has ranged from a low of $1.0387 (Sep 23, 2026) to a high of $2.9076 (Dec 10, 2025), with a median of $1.1692 per EA.
Are there cheaper alternatives to SAXAGLIPTIN HCL 5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SAXAGLIPTIN HCL 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures SAXAGLIPTIN HCL 5 MG TABLET?
SAXAGLIPTIN HCL 5 MG TABLET (NDC 65862082690) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.